Clinical trial
Phase I Trial of Silymarin for Chronic Liver Diseases
NCT00389376 · National Center for Complementary and Integrative Health (NCCIH), NIH · Completed
Key facts
| NCT number | NCT00389376 |
|---|---|
| Title | Phase I Trial of Silymarin for Chronic Liver Diseases |
| Official title | Single and Multiple Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Orally Administered Silymarin (Legalon) in Non-Cirrhotic Subjects With Chronic Hepatitis C or Non-Alcoholic Fatty Liver Disease |
| Acronym | SyNCH |
| Lead sponsor | National Center for Complementary and Integrative Health (NCCIH), NIH |
| Collaborators | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Hepatitis C, Non-Alcoholic Fatty Liver Disease |
| Intervention type | Drug |
| Interventions | Placebo, Silymarin |
| Enrollment | 56 |
| Start date | Nov 1, 2006 |
| Primary completion | Jan 1, 2008 |
| Completion | Feb 1, 2008 |
| First posted | Oct 18, 2006 |
| Last update posted | Feb 20, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: